Modulation of Wnt signaling through inhibition of secreted frizzled-related protein i (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides

Journal of Medicinal Chemistry

Volumn 52, Issue 1, 2009, Pages 105-116

  Moore, William J ^a   Kern, Jeffrey C ^a   Bhat, Ramesh ^a   Commons, Thomas J ^a   Fukayama, Shoichi ^a   Goljer, Igor ^a   Krishnamurthy, Girija ^b   Magolda, Ronald L ^a   Nogle, Lisa ^a   Pitts, Keith ^b   Stauffer, Barb ^a   Trybulski, Eugene J ^a   Welmaker, Gregory S ^a   Wilson, Matthew ^a   Bodine, Peter V N ^a  

^a PFIZER INC   (United States)

^b WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N (TERT BUTYL) 2 [[4 [[[5 (PHENYLSULFONYL) 2 (TRIFLUOROMETHYL)PHENYL]SULFONYL]AMINO]PIPERIDIN 1 YL]CARBONYL]PYRROLIDINE 1 CARBOXAMIDE; N [1 [1 (3,3 DIMETHYLBUTANOYL)PROLYL]PIPERIDIN 4 YL] 5 (PHENYLSULFONYL) 2 (TRIFLUOROMETHYL)BENZENESULFONAMIDE; N [1 [1 (3,3 DIMETHYLBUTYL)PROLYL]PIPERIDIN 4 YL] 5 (PHENYLSULFONYL) 2 (TRIFLUOROMETHYL)BENZENESULFONAMIDE; PIPERIDINYLDIPHENYLSULFONYL SULFONAMIDE; SECRETED FRIZZLED RELATED PROTEIN 1; SULFONAMIDE; TERT BUTYL 2 [[4 [[[5 (PHENYLSULFONYL) 2 (TRIFLUOROMETHYL)PHENYL]SULFONYL]AMINO]PIPERIDIN 1 YL]CARBONYL]PYRROLIDINE 1 CARBOXYLATE; UNCLASSIFIED DRUG; WAY 316606; WAY 362692; WNT PROTEIN; FRIZZLED RELATED PROTEIN-1; PIPERIDINE; PIPERIDINE DERIVATIVE; PROTEIN; SULFANILAMIDE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; DRUG EFFECT; DRUG SYNTHESIS; MOUSE; NEWBORN; NONHUMAN; OSTEOPOROSIS; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; GENETICS; HUMAN; IC 50; ISOMERISM; METABOLISM; PROTEIN BINDING; REPORTER GENE; SECRETION; SIGNAL TRANSDUCTION; SKULL; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; GENES, REPORTER; HUMANS; INHIBITORY CONCENTRATION 50; ISOMERISM; MICE; MOLECULAR STRUCTURE; PIPERIDINES; PROTEIN BINDING; PROTEINS; SIGNAL TRANSDUCTION; SKULL; STRUCTURE-ACTIVITY RELATIONSHIP; SULFANILAMIDES; WNT PROTEINS;

EID: 59449102727     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801144h     Document Type: Article

References (28)

1. Carmona, R. H. Bone Health and Osteoporosis: A Report of the Surgeon General U.S. Department of Health and Human Services, Public Health Service; Office of the Surgeon General: Rockville, MD,October 14, 2004. Gass, M.; Dawson-Hughes, B. Preventing osteoporosis-related fractures: an overview. Am. J. Med. 2006, 119 (4 Suppl 1), S3-S11.
2. Neer, R. M.; Arnaud, C. D.; Zanchetta, J. R.; Prince, R.; Gaich, G. A.; Reginster, J-Y.; Hodsman, A. B.; Eriksen, E. F.; Ish-Shalom, S.; Genant, H. K.; Wang, O.; Mitlak, B. H.; Mellstrom, D.; Oefjord, E. S.; Marcinowska- Suchowierska, E,; Salmi, J.; Mulder, H.; Halse, J.; Sawicki, A. Z. Effect of Parathyroid Hormone (1 - 34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis. N. Engl. J. Med. 2001, 344, 1434-1441.
3. (a) Kulkarni, N. H.; Halladay, D. L.; Miles, R. R.; Gilbert, L. M.; Frolik, C. A.; Galvin, R. J. S.; Martin, T. J.; Gillespie, M. T.; Onyia, J. E. Effects of parathyroid hormone on Wnt signaling pathway in bone. J. Cell. Biochem. 2005, 95, 1178-1190.
4. (b) Bodine, P. V. N.; Seestaller-Wehr, L.; Kharode, Y. P.; Bex, F. J.; Komm, B. S. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J. Cell. phys. 2007, 210 (2), 352-357.
5. (a) Wodarz, A; Nusse, R. Mechanisms of Wnt signaling in development. Ann. Rev. Cell Dev. Biol. 1998, 14, 59-88.
6. (b) Baron, R.; Rawadi, G.; Roman-Roman, S. Wnt signaling: a key regulator of bone mass. Curr. Top. Dev. Biol. 2006, 76, 103-127.
7. Kawano, Y.; Kypta, R. Secreted antagonists of the Wnt signalling pathway. J. Cell Sci. 2003, 116 (13), 2627-2634.
8. (a) Rattner, A.; Hsieh, J. C.; Smallwood, P. M.; Gilbert, D. J.; Copeland, N. G. Jenkins, N. A.; Nathans, J. A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. Proc. Natl. Acad. Sci. 1997, 94, 2859-2863.
9. (b) Jones, S. E.; Jomary, C. Secreted frizzled-related proteins: searching for relationships and patterns. BioEssays 2002, 24, 811-820.
10. Chong, J. M.; Uren, A.; Rubin, J. S.; Speicher, D. W. Disulfide bond assignments of secreted Frizzled-related protein-1 provide insights about frizzled homology and netrin modules. J. Biol. Chem. 2002, 277 (7), 5134-5144.
11. Roman-Roman, S.; Shi, D.-L.; Stiot, V.; Hay, E.; Vayssiere, B.; Garcia, T.; Baron, R.; Rawadi, G. Murine Frizzled-1 Behaves as an Antagonist of the Canonical Wnt/b-Catenin Signaling. J. Biol. Chem. 2004, 279 (7), 5725-5733.
12. (a) Bodine, P. V. N.; Billiard, J.; Moran, R. A.; Ponce-de-Leon, H.; McLarney, S.; Mangine, A.; Bhat, R., A.; Stauffer, B.; Green, J.; Stein, G. S.; Lian, J. B.; Komm, B. S. The Wnt antagonist secreted frizzled- related protein-1 controls osteoblast and osteocyte apoptosis. J. Cell. Biochem. 2005, 96, 1212-1230.
13. (b) Bodine, P. V. N.; Robinson, J. A.; Bhat, R. A.; Billiard, J.; Bex, F. J.; Komm, B. S. The role of Wnt signaling in bone and mineral metabolism. Clin. Rev. Bone Miner. Metabol. 2006, 4, 73-96.
14. Bodine, P. V. N.; Zhao, W.; Kharode, Y. P.; Bex, F. J.; Lambert, A.-J.; Goad, M. B.; Gaur, T.; Stein, G. S.; Lian, J. B.; Komm, B. S. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol. Endocrinol. 2004, 18, 1222-1237.
15. (a) Moore, W. J.; Kern, J. C.; Commons, T. J.; Wilson, M. A.; Welmaker, G. S.; Trybulski, E. J.; Pitts, K.; Krishnamurthy, G.; Stauffer, B.; Bhat, R.; Fukayama, S.; Upthagrove, A. L.; Bodine, P. V. N. Anabolic activity and pharmacokinetic profiles of secreted frizzled-related protein-1 (sFRP-1) antagonists. Abstracts of Papers, 234th ACS National Meeting, Boston, MA, August 19-23, 2007, American Chemical Society: Washington, DC, 2007; MEDI-385.
16. (b) Kern, J. C.; Moore, W. J.; Commons, T. J.; Woodworth, R. P.; Wilson, M. A.; Welmaker, G. S.; Trybulski, E. J.; Pitts, K.; Krishnamurthy, G.; Stauffer, B.; Bhat, R.; Bodine, P. V. N. Diaryl sulfone sulfonamides as secreted frizzled-related protein-1 (sFRP-1) antagonists: SAR and optimization. Abstracts of Papers, 234th ACS National Meeting, Boston, MA, August 19- 23, 2007, American Chemical Society: Washington, DC, 2007; MEDI-387.
17. Welmaker, G. S.; Wilson, M. A.; Moore, W. J.; Kern, J. C.; Trybulski, E. J.; Magolda, R. L.; Pitts, K.; Krishnamurthy, G.; Stauffer, B.; Bhat, R.; Bodine, P. V. N. Design and synthesis of fluorescent probes for the development of a binding assay for the identification of secreted frizzled-related protein-1 (sFRP-1) antagonists. Abstracts of Papers, 234th ACS National Meeting, Boston, MA, August 19- 23, 2007, American Chemical Society: Washington, DC, 2007; MEDI-389.
18. Gopalsamy, A.; Moore, W. J.; Kern, J. C.; Molinari, A. J.; Shi, M.; Welmaker, G. S.; Wilson, M. A.; Krishnamurthy, G.; Commons, T. J.; Webb, M. B.; Woodworth, R. P. Preparation of diarylsulfone sul- fonamides and their use as secreted frizzled related protein-1 modulators for bone disorders such as osteoporosis. U.S. Patent 2006/0276464, 2006.
19. (a) Clark, J. H.; McClinton, M. A.; Jones, C. W.; Landon, P.; Bishop, D.; Blade, R. J. Tetrahedron Lett. 1989, 30, 2133-2136.
20. (b) Clark, J. H.; McClinton, M. A.; Blade, R. J. J. Chem. Soc., Chem. Commun. 1988, 10, 638-639.
21. Wiemers, D. M.; Burton, D. J. J. Am. Chem. Soc. 1986, 108, 832-834.
22. (a) Lin, K; Wang, S; Julius, M A; Kitajewski, J; Moos, M, Jr; Luyten, F P. The cysteine-rich frizzled domain of Frzb-1 is required and sufficient for modulation of Wnt signaling. Proc. Natl. Acad. Sci. U.S.A. 1997, 94 (21), 11196-11200.
23. (b) Bhat, R. A.; Stauffer, B.; Komm, B. S.; Bodine, P. V. N. Structure-function analysis ofsecreted frizzled-related protein-1 for its Wnt antagonist function. J. Cell. Biol. 2007, 102 (6), 1519-1528.
24. Li, C. H.; Amar, S. Role ofsecreted frizzled-related protein 1 (SFRP1) in wound healing. J. Dent. Res. 2006, 85, 374-378.
25. Kumar, S.; Leontovich, A.; Coenen, M. J.; Bahn, R. S. Gene expression profiling of orbital adipose tissue from patients with Graves' ophthal- mopathy: A potential role for secreted frizzled-related protein-1 in orbital adipogenesis. J. Clin. Endocr. Metab. 2005, 90, 4730-4735.
26. Wang, W.-H.; McNatt, L. G.; Pang, I.-H.; Millar, J. C.; Hellberg, P. E.; Hellberg, M. H.; Steely, H. T.; Rubin, J. S.; Fingert, J. H.; Sheffield, V. C.; Stone, E. M.; Clark, A. F. Increased expression of the WNT antagonist sFRP-1 in glaucoma elevates intraocular pressure. J. Clin. Invest. 2008, 118, 1056-1064.
27. (a) Mundy, G.; Garrett, R.; Harris, S.; Chan, J.; Chen, D.; Rossini, G.; Boyce, B.; Zhao, M.; Gutierrez, G. Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286, 1946-1949.
28. (b) Traianedes, K.; Dallas, M. R.; Garrett, I. R.; Mundy, G. R.; Bonewald, L. F. 5-Lipoxygenase metabolites inhibit bone formation in vitro. Endocrinology 1998, 139, 3178-3184.